Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) started the day on May 17, 2021, with a price increase of 3.76% at $1.38. During the day, the stock rose to $1.42 and sunk to $1.3001 before settling in for the price of $1.33 at the close. Taking a more long-term approach, SLRX posted a 52-week range of $0.63-$3.50.
Meanwhile, its Annual Earning per share during the time was 60.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 76.60%. This publicly-traded company’s shares outstanding now amounts to $44.73 million, simultaneously with a float of $44.00 million. The organization now has a market capitalization sitting at $56.65 million. At the time of writing, stock’s 50-day Moving Average stood at $1.3516, while the 200-day Moving Average is $1.1556.
If we measure the efficiency of the company that is accounted for 9 employees. It has generated 581,478 per worker during the last fiscal year. Meanwhile, its income per employee was -816,917. The stock had 2.71 Receivables turnover and 0.27 Total Asset turnover. For the Profitability, stocks operating margin was -148.78 and Pretax Margin of -140.49.
Salarius Pharmaceuticals Inc. (SLRX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Salarius Pharmaceuticals Inc.’s current insider ownership accounts for 0.30%, in contrast to 20.70% institutional ownership. According to the most recent insider trade that took place on Aug 21, this organization’s Director bought 4,000 shares at the rate of 0.98, making the entire transaction reach 3,920 in total value, affecting insider ownership by 11,350. Preceding that transaction, on Aug 19, Company’s Chief Executive Officer bought 2,000 for 1.01, making the whole transaction’s value amount to 2,020. This particular insider is now the holder of 2,000 in total.
Salarius Pharmaceuticals Inc. (SLRX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/30/2020, the organization reported -$0.1 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.11) by $0.01. This company achieved a net margin of -140.49 while generating a return on equity of -44.91. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
Salarius Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 76.60% and is forecasted to reach -0.28 in the upcoming year.
Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Trading Performance Indicators
Let’s observe the current performance indicators for Salarius Pharmaceuticals Inc. (SLRX). The Stock has managed to achieve an average true range (ATR) of 0.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.89.
In the same vein, SLRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.58, a figure that is expected to reach -0.06 in the next quarter, and analysts are predicting that it will be -0.28 at the market close of one year from today.
Technical Analysis of Salarius Pharmaceuticals Inc. (SLRX)
If we take a close look at the recent performances of Salarius Pharmaceuticals Inc. (NASDAQ: SLRX), its last 5-days Average volume was 1.03 million that shows plunge from its year to date volume of 2.12 million. During the previous 9 days, stock’s Stochastic %D was recorded 68.42% While, its Average True Range was 0.1244.
Raw Stochastic average of Salarius Pharmaceuticals Inc. (SLRX) in the period of the previous 100 days is set at 21.31%, which indicates a major fall in contrast to 87.10% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 65.16% that was lower than 121.91% volatility it exhibited in the past 100-days period.